CALC — CalciMedica, Inc.

Is CALC overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

CalciMedica, Inc. (CALC) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $1.60. The rating moved from Strong Oversold to Oversold on September 26, 2026.

See all oversold Healthcare stocks →

AI analysis

CalciMedica, Inc. (CALC) is a small clinical-stage biotechnology company whose near-term outlook is dominated by pipeline binary events, financing needs and limited public disclosure. The prevailing market tone is risk‑off with light volumes, which typically compresses small‑cap biotech valuations and makes capital raises more dilutive. Absent an imminent clinical readout, partner announcement, or clearer cash‑runway visibility, upside catalysts are limited in the next 1–4 weeks while downside from funding or adverse trial/regulatory news remains elevated. Over a longer horizon, positive clinical data or licensing deals would materially improve prospects, but payer/pricing headwinds and macro funding constraints present meaningful obstacles in the interim.

Key factors

  • Early-stage/small-cap biotech profile with limited public financial disclosure available (EDGAR comparison not available)
  • No clear near-term commercial revenues; valuation driven by pipeline, clinical-readout cadence, and partner interest
  • Current market environment is risk-off with defensive flows and light volumes, reducing appetite for speculative healthcare names
  • Policy/payer pressure (Medicare drug-price negotiations) increases longer‑term pricing and access uncertainty for specialty drugs
  • Potential upside from positive clinical data or a licensing/partnership event that would materially de‑risk development and provide capital
  • Low liquidity and likely sensitivity to dilution given funding needs typical of clinical-stage biotechs

Risks

  • Clinical development failure or delayed readouts creating sharp re-pricing
  • Insufficient cash runway or need to raise capital via equity dilution at depressed prices
  • Regulatory setbacks or slower-than-expected approvals and reimbursement decisions
  • Macro risk-off environment and IPO/financing window cooling reducing strategic options and partner interest
  • Downward pricing pressure from ongoing Medicare negotiation and payer cost-containment actions
  • Very low trading volume and concentration risk leading to outsized moves on limited news

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for CALC — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.